Specify a stock or a cryptocurrency in the search bar to get a summary
Collegium Pharmaceutical Inc
COLLCollegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts. Address: 100 Technology Center Drive, Stoughton, MA, United States, 02072
Analytics
WallStreet Target Price
42.5 USDP/E ratio
14.4586Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures COLL
Dividend Analytics COLL
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History COLL
Stock Valuation COLL
Financials COLL
Results | 2019 | Dynamics |